Applying the Phenotype Approach for Rosacea to Practice and Research

J Tan
M Berg
R L Gallo
James Q. Del Rosso
Touro College, jqdelrosso@yahoo.com

Follow this and additional works at: https://touroscholar.touro.edu/tuncom_pubs

Part of the Dermatology Commons

Recommended Citation
Tan, J., Berg, M., Gallo, R. L., & Del Rosso, J. Q. (2018). Applying the phenotype approach for rosacea to practice and research. British Journal of Dermatology, 179(3), 741-746. doi:10.1111/bjd.16815
Applying the phenotype approach for rosacea to practice and research*

J. Tan, M. Berg, R.L. Gallo and J.Q. Del Rosso

1Department of Medicine, Western University, Windsor, ON, Canada
2Department of Dermatology, Uppsala University, Uppsala, Sweden
3Department of Dermatology, University of California San Diego, La Jolla, CA, U.S.A.
4Department of Dermatology, Touro University Nevada, Henderson, NV, U.S.A.

Linked Editorial: Thyssen. B J Dermatol 2018; 179:551–552.

Summary

Background Rosacea diagnosis and classification have evolved since the 2002 National Rosacea Society expert panel subtype approach. Several working groups are now aligned to a more patient-centric phenotype approach, based on an individual’s presenting signs and symptoms. However, subtyping is still commonplace across the field and an integrated strategy is required to ensure widespread progression to the phenotype approach.

Objectives To provide practical recommendations that facilitate adoption of a phenotype approach across the rosacea field.

Methods A review of the literature and consolidation of rosacea expert experience.

Results We identify challenges to implementing a phenotype approach in rosacea and offer practical recommendations to overcome them across clinical practice, interventional research, epidemiological research and basic science.

Conclusions These practical recommendations are intended to indicate the next steps in the progression from subtyping to a phenotype approach in rosacea, with the goals of improving our understanding of the disease, facilitating treatment developments and ultimately improving care for patients with rosacea.

What’s already known about this topic?

- Rosacea diagnosis and classification have evolved from a subtype to a phenotype approach.
- Adoption of the phenotype approach has begun, but more widespread adoption and support across the field are required to ensure a complete transition.

What does this study add?

- We offer practical guidance for clinical practice, interventional and epidemiological research, and basic science, to help overcome challenges and facilitate comprehensive uptake of the phenotype approach in rosacea.

Rosacea diagnosis and classification have evolved. In 2002, the National Rosacea Society (NRS) expert panel proposed diagnostic criteria for rosacea and an associated subtype-based classification that grouped the most common presentations according to disease features. These diagnostic criteria and the subtype classification have guided the majority of subsequent publications on rosacea diagnosis and treatment. However, progress in rosacea research over the last decade has revealed important limitations of this approach. As a consequence, three working groups [the American Acne and Rosacea Society (AARS), the global rosacea consensus expert panel (ROSCO) and the NRS] have formalized what many dermatologists already do in clinical practice and updated the methodology for diagnosis based on phenotypes of the disease.

© 2018 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
The recommendations for a phenotype approach to rosacea, where the disease is diagnosed and classified according to an individual’s presenting features instead of those grouped by subtypes, acknowledge the limitations of subtyping, and build on previous recommendations to propose an approach based on an individual patient’s presenting signs and symptoms. Table 1 shows a comparison of rosacea according to the NRS 2002 subtype classification and the aligned 2017 ROSCO and revised 2017 NRS phenotype recommendations. The features listed under the 2017 system can be combined into any presentation, provided the diagnostic criteria are met. Conversely, the previous 2002 subtype system combined multiple features into the erythematotelangiectatic, papulopustular, phymatous and ocular subtypes.1,11,13

Elements of a phenotype approach have been incorporated into recent national treatment recommendations, which advocate targeted treatment of individual rosacea features.15–18 However, subtyping is still commonplace in numerous recent publications.19,20 In order to promote wider implementation of a phenotype approach, it is important first to identify challenges preventing this transition and then to develop strategies to address those challenges.21

Common challenges to implementation include: poor support and organizational structures within the healthcare system; insufficient knowledge, awareness or skill; lack of resources including time; and uncertainty over the legitimacy of new recommendations.22 In the present publication, we identify challenges to implementation of a phenotype approach across clinical practice, interventional research, epidemiological research and basic science in rosacea. We then make practical recommendations to facilitate assessment, management and research progression inclusive of the individual experience of disease.

**Materials and methods**

A panel of four dermatologists defined the framework for possible recommendation categories pertaining to clinical practice, interventional research, epidemiological research and basic science in rosacea. A literature search was performed to assess the current approach to rosacea practice and research within these four areas. Hits were limited to articles published between April 2015 and January 2018 to cover the period after publication of the most recent Cochrane systematic review on interventions for rosacea.19 The authors identified challenges to implementation of a phenotype approach based on the literature search results and their experience in the field. They then consolidated and refined their recommendations through discussion.

**Challenges**

Fifteen years’ usage of the NRS 2002 rosacea diagnostic criteria and subtyping in textbooks, academic papers and podium presentations has engrained these concepts in dermatology. There is a need for clinicians, researchers, authors and scientific reviewers to be apprised of current modifications. Until then, the subtype concept with its shortcomings will persist.

Inconsistent nomenclature is a field-wide issue that confounds the reporting of numerous studies. The terms ‘rosacea’ and ‘acute rosacea’ are used variably and often nonspecifically, as are definitions of certain features (e.g. persistent and transient erythema can be confounded with perileisional inflammation). There is a need for better differentiation in research studies of the phenotype of the patients being studied.

The challenges in interventional research mostly centre on existing conventions and protocols. As the transition towards a phenotype approach is a recent development, little documentation exists to demonstrate its benefits and convince stakeholders of its value. In addition, older treatments assessed according to subtype in previous literature (e.g. Cochrane systematic reviews) will be disqualified, while new, smaller studies may be required to show an effect of a therapy, either alone or in combination, on specific features.

Industry sponsors of interventional research using subtype-based measures may be reluctant to replace these with outcomes for individual features, unless the value has already

---

**Table 1** Summary of recommendations for rosacea diagnosis, according to the 2002 subtype and 2017 phenotype approaches

| NRS 2002 ◊ | Primary (diagnostic) features | Secondary features |
|-----------|-------------------------------|--------------------|
| Flushing/transient erythema | Papules and pustules | Telangiectasia |
| Persistent/transient erythema | | |
| ROSCO 2017/NRS 201711,13 | Diagnostic features ◊ | Major features ◊ |
| Persistent centrofacial erythema | Transient centrofacial erythema | Inflammatory papules/pustules | Telangiectasia |
| with periodic intensification | Inflammatory papules/pustules | Ocular manifestations |
| by potential trigger factors | Telangiectasia | |
| Phymatous changes | Ocular manifestations | |
| Minor/secondary features | Burning/stinging sensation | Oedema |
| Dry sensation/appearance | | |

According to the 2002 subtyping system, multiple features were grouped into defined subtypes. The 2017 phenotyping system allows various combinations of diagnostic, major and minor features into an individual phenotype. NRS, National Rosacea Society; ROSCO, global ROSacea Consensus panel. ◊The presence of one or more of these with a central facial distribution is indicative of rosacea. ◊Individually diagnostic. ◊A combination of at least two is diagnostic, in the absence of a diagnostic feature. Individual publications also discuss the importance of proper history taking, exclusion criteria and trigger factors for specific features.
been demonstrated. We believe that the phenotype approach allows investigators to assign outcomes for one or more rosacea features best addressed by investigational treatments, compared with multiple features in some existing scales. Standardizing these outcome measures would also facilitate interstudy comparisons and combining of results. Furthermore, improved severity scales that focus on individual features should be more accurate than those in current usage, thereby offering the potential for a smaller trial population to demonstrate significance. This could translate to lower costs of trials.

Study protocols are a further challenge for adoption of a phenotype approach in interventional and epidemiological research, due to the engrained subtype-based nomenclature. Some researchers accept implicitly that a singular examination predicates the features of an individual patient with rosacea; this fails to account for fluctuation of some features over time (e.g. papules/pustules or erythema with phyma) and may provide an incomplete disease representation for the patient. This is also hindered by the lack of long-term epidemiological studies in the field. Furthermore, darker skin pigment phototypes are under-represented in epidemiological studies, due to difficulties in diagnosis that often fail to account for the presence of rosacea in these patients.

In basic science, several specific factors also hinder the progression to a phenotype approach to rosacea. These include limited funding opportunities, absence of patient registries or clinical tissue biobanks, and the lack of a satisfactory animal model for rosacea.

Results

Challenges and recommendations for clinical practice

A phenotype approach to rosacea management could improve patient outcomes by targeting the aspects most bothersome to the patient. It also facilitates use of combination therapy when necessary, to address multiple presenting features and optimize clinical outcomes and quality of life. Rosacea treatment is moving towards such an approach, which is now recommended by several regional and national bodies in clinical practice.

However, further support is needed to facilitate its implementation into daily practice.

Assessment of disease severity and patient impact (including quality of life) would also benefit from a phenotype approach. Several groups have commented that existing scales for assessing these are not sufficient, including the only rosacea-specific tool (Rosacea Quality of Life; RosAQoL), which both omits certain features and lacks indication of a clinically relevant difference. As such, there is a need for validated tools that are easy to use in the clinic and address all skin pigment types.

Recommendations

1. Update the language surrounding rosacea diagnosis and classification to discontinue the concept of subtyping.

2. Initiate an international, multisponsor core meeting of stakeholders to develop a communications plan for the phenotype concept.

3. Educate patients and healthcare providers to raise awareness and improve understanding of the phenotype nomenclature.

4. Demonstrate the proven clinical value of making the change to phenotyping and reinforce the shortcomings of the subtype approach.

5. Develop simple clinical tools for physicians to use with their patients that are applicable to all skin pigment types.

Challenges and recommendations for interventional research

Assessment methodologies used in rosacea clinical trials are variable and could be of higher quality. The subtype approach is likely to hinder treatment progress in two ways. Firstly, a treatment directed at one dimension of a subtype (e.g. inflammatory papules or pustules in papulopustular rosacea) may fail in clinical trials because it does not address the subtype’s other dimensions (i.e. persistent erythema). Secondly, the multiple dimensions of a subtype can confound commonly used rosacea severity scales, as with clinical practice. In clinical trials, this can interfere with study and assessment of the course of singular disease features.
Many clinical trials in rosacea still recruit patients using subtype-based inclusion criteria and assess treatment outcomes according to those subtypes (for example, using the NRS Rosacea Clinical Scorecard). However, although some more recent studies have still recruited patients by subtype, they have assessed therapeutic response by change in individual features. This is a positive step towards a phenotype approach.

**Recommendations**

1. Establish credible, standardized clinical and patient-reported measures for the most common features to make them acceptable to researchers, industry and regulatory authorities.

   → Industry may be especially interested in moving forward new drug entities to address specific signs and symptoms instead of the multiple dimensions required with subtypes.

2. Develop and publish real-life examples of phenotype use in interventional research, to validate the approach and demonstrate best practice throughout the field.

   → Could be based on the five-part AARS series, suggesting that a phenotype evaluation of rosacea correlates with therapy.

   → Enhance with the support of a larger group of interested researchers and clinicians.

**Challenges and recommendations for epidemiological research**

Epidemiological studies in rosacea provide widely varying disease prevalence estimates. Beyond valid differences relating to location and population differences, this variation may be a result of differences in case determination and study design, and variable assessment of individual features due to differences in skin pigment type.

Characterizing by subtype confounds epidemiological studies because many patients present with varied features, so are inadequately described. For example, there is no subtype for a patient presenting solely with persistent centrofacial erythema without transient erythema and flushing, or vice versa. Similarly, a patient presenting with fixed erythema, inflammatory papules and pustules and telangiectasia could fall into both the erythematotelangiectatic and papulopustular categories, and so might be counted twice. Furthermore, certain features can spontaneously remit and recur, which may result in the patient being classified in multiple subtype categories dependent on the time of observation.

Refining diagnostic criteria based on a phenotype approach could improve the consistency and quality of epidemiological data, which would continue to benefit rosacea diagnosis and overall disease management.

**Recommendations**

1. Facilitate longitudinal epidemiological studies in rosacea that consider the potential for fluctuation of certain features.

   → There would be great value in extension to a global registry, which would provide longitudinal real-world evidence to bolster epidemiological data and a phenotype treatment approach.

2. Include and support regional groups from all continents in epidemiological studies, to ensure representation of all skin pigment types.

**Challenges and recommendations for basic science**

Despite ongoing research, the pathophysiology of rosacea remains uncertain. Cutaneous rosacea subtypes demonstrate both differences and overlap in histological, immunohistological and gene expression markers. As such, there is limited information on molecular markers responsible for the initiation and perpetuation of rosacea’s various cutaneous features. Therefore, subtype classification may be hindering biomarker identification for individual features.

**Recommendations**

1. Work towards highlighting the need for national initiatives to support research in rosacea.

   → For example, the National Institutes for Health Request for Applications.

2. Extend clinical practice updates that emphasize phenotype nomenclature to basic science.

   → Would be of similar benefit in standardizing assessments.

3. Reinforce the concept of phenotype variation over time, as with epidemiological research.

   → Would encourage specimen collections at multiple time points to assess the chronic nature of the disease.

4. Interrogate existing data to unmask key specific factors in rosacea pathophysiology and identify which treatments have the largest or fastest impact on disease.

**Discussion**

Herein we have discussed strategies to support the phenotype approach in rosacea across clinical practice, interventional and epidemiological research, and basic science. Several strategies span multiple areas, which reflects the need for an integrated approach to ensure consistent and comprehensive uptake.
Audit and feedback lead to small but potentially important improvements in professional practice. It is therefore important to measure the effectiveness of the phenotype approach as it becomes more widely used, which will both enable sharing of successes to promote a virtuous circle of uptake and identify areas for improvement. In studies assessing the effectiveness of clinical guideline dissemination and implementation, the most widely used strategies for measuring change were medical record audit, computerized databases and health practitioner questionnaire or interview. These align with several recommendations from the World Health Organization to measure specific behaviour change strategies.\(^{37}\) These recommendations included the need to consider all skin pigment types when developing tools and diagnostic recommendations.\(^{11}\)

The Expert Recommendations for Implementing Change project has compiled a number of implementation strategies for guideline implementation.\(^{39}\) We have identified those most relevant to the rosacea field and summarized them in Table 2, together with comment on the context of each and potential strategies to measure effectiveness.

Our recommendations are limited by the fact that this is an evolving field of inquiry, meaning future advances may inform modification of signs and symptoms, and subsequent adjustment to our suggested language updates and tools. Furthermore, even given an objective tool, the severity of some signs can be subjective; for example, some cultures may consider persistent mild centrofacial erythema presenting as ‘rosy cheeks’ to be a normal or healthy variation. There are also limitations in the use of persistent centrofacial erythema as a definitive diagnostic feature in dark skin phototypes, which will require specific guidance from future work to ensure consistent diagnosis and classification across the patient spectrum.

The transition to a phenotype approach in rosacea is underway; however, there is still significant work to be done to ensure a comprehensive uptake. These practical recommendations are intended to indicate the next steps in this process, with the goals of improving our understanding of the disease, facilitating treatment developments, and ultimately improving care for patients with rosacea.

### Acknowledgments

Medical writing and editorial assistance was provided by Ellie Hughes, PhD; Victoria Smith, BSc (Hons) and Holly Gilbert-Jones, PhD, of Ogilvy Healthworld, London, U.K.
References

1. Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46:584–7.

2. Dahl MV. Rosacea subtypes: a treatment algorithm. Cuts 2004; 74 (3 Suppl.):21–7, 32–4.

3. Odom R. The nosology of rosacea. Cuts 2004; 74 (3 Suppl.):5–8, 32–4.

4. Powell FC. Clinical practice. Rosacea. N Engl J Med 2005; 352:793–803.

5. Goldgar C, Kealey DJ, Houchins J. Treatment options for acne rosacea. Am Fam Physician 2009; 80:461–8.

6. Odom R, Dahl M, Dover J et al. Standard management options for rosacea, Part 2: options according to subtype. Cuts 2009; 84:97–104.

7. Reinholt M, Tietze JK, Kilian K et al. Rosacea – SI Guideline. J Dtsch Dermatol Gs 2013; 11:768–80.

8. Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Coment Invest Dermatol 2015; 8:159–77.

9. Tan J, Steinhoff M, Berg M et al. Shortcomings in rosacea diagnosis and classification. Br J Dermatol 2017; 176:197–9.

10. Del Rosso JQ, Thiboutot D, Gallo R et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 1: a status report on the disease state, general measures, and adjunctive skin care. Cuts 2013; 92:234–40.

11. Tan J, Almeida LMC, Beyew A et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea Consensus (ROSCO) panel. Br J Dermatol 2017; 176:431–8.

12. Schaller M, Almeida LMC, Beyew A et al. Rosacea treatment update: recommendations from the global ROSacea Consensus (ROSCO) panel. Br J Dermatol 2017; 176:465–71.

13. Gallo RL, Granstein RD, Kang S et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol 2018; 78:148–55.

14. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69 (6 Suppl.):S27–35.

15. Asai Y, Tan J, Baiberganova A et al. Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg 2016; 20:432–45.

16. Troisi P, González Otero FM, Ríos Yuli JM et al. [Update and recommendations for the diagnosis and treatment of rosacea in Latin America]. Med Cutan Ibero Lat Am 2016; 44:7–26 (in Spanish).

17. Schaller M, Schöfer H, Homey B et al. Rosacea management: update on general measures and topical treatment options. J Dtsch Dermatol Gs 2016; 14 (Suppl. 6):17–27.

18. Reinholt M, Ruzicka T, Steinhoff M et al. Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy. J Dtsch Dermatol Gs 2016; 14 (Suppl. 6):4–15.

19. van Zuuren EJ, Fedorowicz Z, Carter B et al. Interventions for rosacea. Cochrane Database Syst Rev 2015; 4:CD003262.

20. van Zuuren EJ. Rosacea. N Engl J Med 2017; 377:1754–64.

21. Hakkennes S, Dodd K. Guideline implementation in allied health professions: a systematic review of the literature. Qual Saf Health Care 2008; 17:296–300.

22. Fitzgerald A, Lethaby A. Review of systematic reviews exploring the implementation/uptake of guidelines. Available at: https://www.nice.org.uk/guidance/ph56/evidence/evidence-review-2-43 1762366 (last accessed 31 May 2018).

23. Hopkinson D, Moradi Tuchayi S, Alinia H, Feldman SR. Assessment of rosacea severity: a review of evaluation methods used in clinical trials. J Am Acad Dermatol 2015; 73:138–43.

24. Stein Gold L, Kircik L, Fowler J et al. Long-term safety of ivermectin 1% cream versus azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014; 13:1380–6.

25. Brieche MR, Fedotov VP, Gladichev VY et al. Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. Int J Dermatol 2015; 54:481–7.

26. Taieb A, Ortonne JP, Ruzicka T et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 2015; 172:1103–10.

27. Draelos ZD, Eleszewski BE, Harper JC et al. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cuts 2015; 96:54–61.

28. Del Rosso JQ, Thiboutot D, Gallo R et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 2: a status report on topical agents. Cuts 2013; 92:277–84.

29. Del Rosso JQ, Thiboutot D, Gallo R et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 3: a status report on systemic therapies. Cuts 2014; 93:18–28.

30. Tanghetti E, Del Rosso JQ, Thiboutot D et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 4: a status report on physical modalities and devices. Cuts 2014; 93:71–6.

31. Del Rosso JQ, Thiboutot D, Gallo R et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 5: a guide on the management of rosacea. Cuts 2014; 93:134–8.

32. Tan J, Blume-Peytavi U, Ortonne JP et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol 2013; 169:555–62.

33. Steinhoff M, Buddenkotte J, Aubert J et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc 2011; 15:2–11.

34. Criberier B. Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol 2013; 27:1336–43.

35. Buhl T, Sulk M, Nowak P et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol 2015; 135:2198–208.

36. Ivers N, Jamtvedt G, Flottorp S et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012; 6:CD000259.

37. Hakkennes S, Green S. Measures for assessing practice change in medical practitioners. Implement Sci 2006; 1:29.

38. Wang Z, Norris SL, Bero L. Implementation plans included in World Health Organisation guidelines. Implement Sci 2015; 11:76.

39. Powell BJ, Waltz TJ, Chinman MJ et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci 2015; 10:21.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Appendix S1 Rosacea phenotype checklist.

Powerpoint S1 Journal Club Slide Set.

Video S1 Author video.